Financial Instruments - Narrative (Details)	3 Months Ended		12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) interest_rate_swap	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Derivative [Line Items]
Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales			$ 104,000,000
Equity investments without readily determinable fair values	$ 832,000,000	$ 596,000,000	832,000,000	$ 596,000,000
Unrealized gains recognized on investments in equity securities without readily determinable fair value			56,000,000	110,000,000
Unrealized losses recognized on investments in equity securities without readily determinable fair values			12,000,000	1,000,000
Cumulative upward price adjustment	289,000,000		289,000,000
Cumulative downward price adjustment	19,000,000		19,000,000
Equity securities held through ownership interests in investment funds	598,000,000	1,700,000,000	598,000,000	1,700,000,000	$ 800,000,000
(Gains) losses for equity securities held through ownership interests in investment funds			1,000,000,000	(1,400,000,000)	$ (583,000,000)
Fair value of loans payable and long-term debt, including current portion	26,700,000,000	35,700,000,000	26,700,000,000	35,700,000,000
Debt, carrying amount	30,700,000,000	33,100,000,000	30,700,000,000	33,100,000,000
Factored accounts receivable	2,500,000,000	2,800,000,000
Funds collected from factoring of receivable, held in restricted cash	67,000,000	62,000,000	67,000,000	62,000,000
Cash collateral advanced to counterparties	19,000,000		19,000,000
Cash collateral received from counterparties	66,000,000	164,000,000	66,000,000	164,000,000
2.40% Notes Due 2022
Derivative [Line Items]
Face amount of debt	$ 1,000,000,000		$ 1,000,000,000
Stated interest rate	2.40%		2.40%
2.35% notes due 2022
Derivative [Line Items]
Face amount of debt	$ 1,250,000,000		$ 1,250,000,000
Stated interest rate	2.35%		2.35%
Customer Concentration Risk | Accounts Receivable | McKesson
Derivative [Line Items]
Percentage of accounts receivable represented by customers with largest balances (as percent)			21.00%
Customer Concentration Risk | Accounts Receivable | AmerisourceBergen Corporation
Derivative [Line Items]
Percentage of accounts receivable represented by customers with largest balances (as percent)			20.00%
Customer Concentration Risk | Accounts Receivable | Cardinal Health, Inc.
Derivative [Line Items]
Percentage of accounts receivable represented by customers with largest balances (as percent)			13.00%
Level 2
Derivative [Line Items]
Cash equivalents	$ 11,300,000,000	$ 6,800,000,000	$ 11,300,000,000	$ 6,800,000,000
Interest Rate Swap
Derivative [Line Items]
Number of interest rate derivatives matured | interest_rate_swap			9
Total notional amount of Interest rate derivatives matured			$ 2,250,000,000
Maximum | Derivatives Designated as Hedging Instruments
Derivative [Line Items]
Maximum planning cycle of hedges (less than)			2 years
Maximum | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Maximum planning cycle of hedges (less than)			6 months